Value Analysis GlaxoSmithKline Plc (GSK:LSE)

Value Analysis GlaxoSmithKline Plc (GSK:LSE)

GSK, recently showed up as cheap on earnings data and had a good dividend record so warranted further research.  However, GSK also looked expensive on price to book so some caution was also advisable.

The earnings picture was complicated by a deal done by GSK in 2015 with another drug company, Novartis.  The deal with Novartis has resulted in a big increase in earnings in 2015, but the last Annual Report for 2014 showed relatively low earnings.

Click Add to Basket to purchase this report.